April 12, 2021 Taysha Gene Therapies has acquired exclusive worldwide rights to a clinical-stage adeno-associated virus 9 (AAV9) gene therapy program (TSHA-120) for the treatment of giant axonal neuropathy.
TSHA-120 is currently being evaluated in an ongoing open-label, nonrandomized, dose-escalation clinical trial conducted by the U.S. National Institute of Neurological Disorders and Stroke (NINDS) division of the National Institutes of Health (NIH). The primary end point is safety, and a primary measure of TSHA-120 s clinical efficacy is the Motor Function Measure 32 (MFM32) score. TSHA-120 has demonstrated the potential to improve MFM32 scores in patients. Additional data from the study are expected later this year.
Taysha takes over development of giant axonal neuropathy gene therapy scienceboard.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from scienceboard.net Daily Mail and Mail on Sunday newspapers.
Common antidepressants won t raise risk for bleeding stroke, study says upi.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from upi.com Daily Mail and Mail on Sunday newspapers.